Efficacy and safety of anlotinib combined with 125I seed implantation for iodine-refractory thyroid cancer
Background and objectiveRadioiodine-refractory differentiated thyroid cancer (RAIR-DTC) remains challenging to treat due to a lack of effective therapies. This study aimed to evaluate the efficacy and safety of combining anlotinib with iodine-125 (125I) seed implantation in patients with RAIR-DTC.Me...
Saved in:
| Main Authors: | Zhijun Chen, Xinlan Tang, Liling Tan, Yu Su, Wenjun Wang, Zhen Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1587412/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01) -
Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report
by: Gaoyan Tang, et al.
Published: (2025-04-01) -
New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01) -
Episcleral Iodine-125 radioactive plaque brachytherapy as a salvage treatment for retinoblastoma in the era of intraarterial chemotherapy
by: Ahmet Murat Sarıcı, et al.
Published: (2022-04-01) -
Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)